Ocular Therapeutix Analyst Price Targets

Ocular Therapeutix Inc

OCULNASDAQ

Trade with Public

$6.87

-0.51-6.91%

Últ. Act.: Oct 19, 7:33 AM

$7.27

-0.11-1.49%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Ocular Therapeutix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ocular Therapeutix (OCUL).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy

11Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$22Upside to Avg. PT+205.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Buy	$14
Oct 2, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$23
Sep 29, 2026	Needham	Serge Belanger	Maintained	Buy	$18
Sep 16, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$23
Sep 16, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$25
Aug 4, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$23
Jun 25, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$21→$23
Jun 18, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$21→$25
Jun 18, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$24→$30
May 6, 2026	RBC Capital	Lisa Walter	Maintained	Outperform	$30
May 5, 2026	Needham	Serge Belanger	Maintained	Buy	$18
Apr 13, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$21
Mar 3, 2026	Clear Street	Bill Maughan	PT Raise	Buy	$21→$28
Feb 20, 2026	Needham	Serge Belanger	PT Cut	Buy	$20→$18
Feb 18, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$21
Dec 9, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$21
Dec 8, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Dec 8, 2025	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$19→$21
Nov 25, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$19
Nov 5, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$21

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $25 price target.

Benzinga Newsdesk

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.

Vandana Singh

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $25.

Benzinga Newsdesk

Ocular Therapeutix Inc

Ocular Therapeutix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Why Is Ocular Therapeutix Stock Gaining Monday?

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ocular Therapeutix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Why Is Ocular Therapeutix Stock Gaining Monday?

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

People Also Watch

People Also Watch

Ocular Therapeutix Inc

Ocular Therapeutix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRONeedham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PROHC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Why Is Ocular Therapeutix Stock Gaining Monday?

PROChardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

PROHC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ocular Therapeutix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRONeedham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PROHC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Why Is Ocular Therapeutix Stock Gaining Monday?

PROChardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

PROHC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25